CN105755112B - 结肠直肠癌的诊断 - Google Patents

结肠直肠癌的诊断 Download PDF

Info

Publication number
CN105755112B
CN105755112B CN201511009181.5A CN201511009181A CN105755112B CN 105755112 B CN105755112 B CN 105755112B CN 201511009181 A CN201511009181 A CN 201511009181A CN 105755112 B CN105755112 B CN 105755112B
Authority
CN
China
Prior art keywords
colorectal cancer
kinds
purposes
biomarker
m2pk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201511009181.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105755112A (zh
Inventor
利亚·简·科斯格罗夫
布鲁斯·塔博尔
安东尼·W·伯吉斯
埃都阿德·柯林斯·尼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visual technology biology Pte Ltd
Original Assignee
Visual Technology Biology Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010903140A external-priority patent/AU2010903140A0/en
Application filed by Visual Technology Biology Pte Ltd filed Critical Visual Technology Biology Pte Ltd
Publication of CN105755112A publication Critical patent/CN105755112A/zh
Application granted granted Critical
Publication of CN105755112B publication Critical patent/CN105755112B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201511009181.5A 2010-07-14 2011-07-14 结肠直肠癌的诊断 Active CN105755112B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2010903140 2010-07-14
AU2010903140A AU2010903140A0 (en) 2010-07-14 Diagnostic for colorectal cancer
CN201180034158.5A CN103140760B (zh) 2010-07-14 2011-07-14 结肠直肠癌的诊断

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180034158.5A Division CN103140760B (zh) 2010-07-14 2011-07-14 结肠直肠癌的诊断

Publications (2)

Publication Number Publication Date
CN105755112A CN105755112A (zh) 2016-07-13
CN105755112B true CN105755112B (zh) 2019-06-07

Family

ID=45468816

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180034158.5A Active CN103140760B (zh) 2010-07-14 2011-07-14 结肠直肠癌的诊断
CN201511009181.5A Active CN105755112B (zh) 2010-07-14 2011-07-14 结肠直肠癌的诊断

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201180034158.5A Active CN103140760B (zh) 2010-07-14 2011-07-14 结肠直肠癌的诊断

Country Status (13)

Country Link
US (2) US20130345322A1 (2)
EP (2) EP2829881B1 (2)
JP (1) JP6061344B2 (2)
CN (2) CN103140760B (2)
AU (1) AU2011279555B2 (2)
BR (1) BR112013000745B1 (2)
DK (1) DK2829881T3 (2)
ES (1) ES2653646T3 (2)
IN (1) IN2013CN01129A (2)
NO (1) NO2829881T3 (2)
PT (1) PT2829881T (2)
RU (1) RU2013103995A (2)
WO (1) WO2012006681A1 (2)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103140760B (zh) 2010-07-14 2016-01-27 联邦科学与工业研究组织 结肠直肠癌的诊断
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
MX2013008833A (es) 2011-02-02 2013-12-06 Amgen Inc Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
WO2014023820A1 (en) * 2012-08-09 2014-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic of heart failure
GB201218341D0 (en) * 2012-10-12 2012-11-28 Orign Sciences Ltd Diagnostic method
MX2016012697A (es) * 2014-03-28 2017-05-09 Applied Proteomics Inc Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
EA035674B1 (ru) * 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
CN106191215B (zh) * 2015-04-29 2020-03-24 中国科学院上海生命科学研究院 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用
US10877024B2 (en) * 2015-05-12 2020-12-29 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
CN105219844B (zh) * 2015-06-08 2018-12-14 华夏京都医疗投资管理有限公司 一种筛查十一种疾病的基因标志物组合、试剂盒以及疾病风险预测模型
CN105021828B (zh) * 2015-07-20 2017-07-28 上海交通大学医学院附属新华医院 通过检测三期结直肠肿瘤患者血清预测肿瘤患者预后
CN105567846A (zh) * 2016-02-14 2016-05-11 上海交通大学医学院附属仁济医院 检测粪便中细菌dna的试剂盒及其在大肠癌诊断中的应用
JP6984862B2 (ja) * 2017-03-15 2021-12-22 国立大学法人金沢大学 血中ケモカインをマーカーとして用いた大腸癌の検出
CN107164535A (zh) * 2017-07-07 2017-09-15 沈阳宁沪科技有限公司 一种无创高通量甲基化结肠癌诊断、研究和治疗方法
CN110540588B (zh) * 2018-05-28 2022-08-23 香港中文大学 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用
CN108957014A (zh) * 2018-09-27 2018-12-07 郑州大学第附属医院 结直肠癌血清标志物、表达评估方法、试剂盒及应用
JP2022505676A (ja) * 2018-10-23 2022-01-14 ブラックソーン セラピューティクス インコーポレイテッド 患者のスクリーニング、診断、及び層別化のためのシステム及び方法
CN109504778B (zh) * 2019-01-11 2021-11-09 复旦大学附属中山医院 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型
ES2952139T3 (es) * 2019-03-01 2023-10-27 Advanced Marker Discovery S L Firma proteica para el diagnóstico de cáncer colorrectal y/o etapa precancerosa del mismo
JP7300660B2 (ja) * 2019-04-03 2023-06-30 京都府公立大学法人 大腸がんの検出方法
JP7032764B2 (ja) * 2019-04-03 2022-03-09 京都府公立大学法人 大腸がんの検出方法
GB201906199D0 (en) * 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
US20220378877A1 (en) * 2019-11-13 2022-12-01 University Of Virginia Patent Foundation Treatment of clostridium difficile infections
EP3835789A1 (en) 2019-12-13 2021-06-16 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Biomarker panel for diagnosing colorectal cancer
WO2022130597A1 (ja) * 2020-12-18 2022-06-23 国立大学法人東北大学 推定装置、推定方法、推定プログラム、生成装置、及び、推定システム
CA3202255A1 (en) * 2020-12-21 2022-06-30 Hayley WARSINSKE Markers for the early detection of colon cell proliferative disorders
EP4327100A4 (en) * 2021-04-20 2025-02-26 Vision Tech Bio Pty Ltd Biomarkers for colorectal cancer
WO2023015354A1 (en) * 2021-08-11 2023-02-16 Vision Tech Bio Pty Ltd Method of detecting adenoma
WO2023128419A1 (ko) * 2021-12-31 2023-07-06 주식회사 이노제닉스 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용
WO2023128429A1 (ko) * 2021-12-31 2023-07-06 주식회사 이노제닉스 대장암 및 진행 선종의 선별 검사 방법 및 그 응용
CN114594259B (zh) * 2022-04-22 2022-09-13 北京易科拜德科技有限公司 一种新型的用于结直肠癌预后预测和诊断的模型及其应用
PL441319A1 (pl) * 2022-05-31 2023-12-04 Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro
CN116219007A (zh) * 2022-09-15 2023-06-06 绍兴积准生物科技有限公司 检测结直肠癌的生物标志物组及其应用
WO2026068794A1 (en) 2024-09-30 2026-04-02 Roche Diagnostics International Ag Auto-antibodies to anpep for assessing colorectal cancer (crc) or a precancerous condition thereof
WO2026068798A1 (en) 2024-09-30 2026-04-02 Roche Diagnostics International Ag Sox9 for assessing colorectal cancer (crc) or a precancerous condition thereof
WO2026068795A2 (en) 2024-09-30 2026-04-02 Roche Diagnostics International Ag Clec3b for assessing colorectal cancer (crc) or a precancerous condition thereof
CN119688988A (zh) * 2024-11-25 2025-03-25 中国医学科学院肿瘤医院 Timp1和foxp3作为诊断结直肠癌的生物标志物组合及其应用
CN121186364B (zh) * 2025-11-25 2026-04-14 长兴固容生物科技有限公司 一种用于胃癌筛查、诊断的标志物组及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009037572A2 (en) * 2007-06-04 2009-03-26 Diagnoplex Biomarker combinations for colorectal cancer
WO2009126543A1 (en) * 2008-04-08 2009-10-15 Nuclea Biomarkers, Llc Biomarker panel for prediction of recurrent colorectal cancer
EP2145190A1 (en) * 2007-05-10 2010-01-20 Roche Diagnostics GmbH Use of timp-1 as a marker for colorectal cancer
CN103140760B (zh) * 2010-07-14 2016-01-27 联邦科学与工业研究组织 结肠直肠癌的诊断

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
JP2004198419A (ja) * 2002-12-13 2004-07-15 Bayer Healthcare Llc Ｔｉｍｐ１を用いた検出方法
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
ATE491953T1 (de) * 2003-09-15 2011-01-15 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
BRPI0401830A (pt) 2004-05-25 2006-01-17 Bentonit Uniao Nordeste Sa Processo de produção de pós granulados secos
WO2008005469A2 (en) 2006-06-30 2008-01-10 Schering Corporation Igfbp2 biomarker
US9060961B2 (en) 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
WO2008100913A2 (en) 2007-02-12 2008-08-21 The Johns Hopkins University Early detection and prognosis of colon cancers
BRPI0807384A2 (pt) * 2007-02-27 2014-05-20 Sentoclone Ab Método de uma etapa para detecção direta ou simultânea de uma célula cancerosa ou elemento de célula cancerosa em uma amostra biológica, kit para uso em um método, base de dados, método para indetificar células cancerosas, e, uso de uma base de dados.
WO2008116178A2 (en) * 2007-03-21 2008-09-25 Vanderbilt University Systems and methods for diagnosis and prognosis of colorectal cancer
EP2559771A3 (en) * 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US20090017463A1 (en) * 2007-07-10 2009-01-15 Vanderbilt University Methods for predicting prostate cancer recurrence
US20100111969A1 (en) * 2008-10-31 2010-05-06 Apogenix Gmbh Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors
CN102300578A (zh) * 2008-12-01 2011-12-28 延寿有限责任公司 用于改变健康、安康和寿命的方法和组合物
CN102308212A (zh) * 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
US9354233B2 (en) * 2009-02-20 2016-05-31 The Regents Of The University Of California A+ biomarker assays
US20110177525A1 (en) * 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2145190A1 (en) * 2007-05-10 2010-01-20 Roche Diagnostics GmbH Use of timp-1 as a marker for colorectal cancer
WO2009037572A2 (en) * 2007-06-04 2009-03-26 Diagnoplex Biomarker combinations for colorectal cancer
WO2009126543A1 (en) * 2008-04-08 2009-10-15 Nuclea Biomarkers, Llc Biomarker panel for prediction of recurrent colorectal cancer
CN103140760B (zh) * 2010-07-14 2016-01-27 联邦科学与工业研究组织 结肠直肠癌的诊断

Also Published As

Publication number Publication date
CN105755112A (zh) 2016-07-13
AU2011279555B2 (en) 2016-10-20
EP2593795A4 (en) 2014-01-22
JP2013533977A (ja) 2013-08-29
NO2829881T3 (2) 2018-01-20
BR112013000745A2 (pt) 2016-05-24
US10877039B2 (en) 2020-12-29
CN103140760A (zh) 2013-06-05
AU2011279555A1 (en) 2013-01-31
EP2829881A2 (en) 2015-01-28
JP6061344B2 (ja) 2017-01-18
RU2013103995A (ru) 2014-08-20
EP2593795A1 (en) 2013-05-22
EP2829881B1 (en) 2017-08-23
US20130345322A1 (en) 2013-12-26
DK2829881T3 (en) 2017-12-04
CN103140760B (zh) 2016-01-27
WO2012006681A1 (en) 2012-01-19
PT2829881T (pt) 2017-11-29
BR112013000745B1 (pt) 2021-02-02
US20170205414A1 (en) 2017-07-20
ES2653646T3 (es) 2018-02-08
IN2013CN01129A (2) 2015-07-31
EP2829881A3 (en) 2015-05-13

Similar Documents

Publication Publication Date Title
CN105755112B (zh) 结肠直肠癌的诊断
US8586006B2 (en) Organ-specific proteins and methods of their use
CN112345755A (zh) 乳腺癌的生物标志物及其应用
CN103582815A (zh) 用于卵巢癌的生物标志物组、诊断方法和测试试剂盒
CN113439212B (zh) 用于确定侵袭性前列腺癌的生物标志物组合
KR20100126258A (ko) 부인과 질환을 탐지하기 위한 분석법
KR102208140B1 (ko) 전립선암의 바이오마커 검출에서 사용하기 위한 방법 및 어레이
KR102018205B1 (ko) 대장암 진단용 조성물 및 상기 조성물을 이용한 대장암 진단 방법
CN117120847A (zh) 肺癌的检测方法
CN116413430B (zh) 一种用于肝癌早期预测的自身抗体/抗原组合及检测试剂盒
US20240393336A1 (en) Biomarkers for colorectal cancer
KR102018209B1 (ko) 위암 진단용 조성물 및 상기 조성물을 이용한 위암 진단 방법
CN105510586B (zh) 用于肺癌诊断的试剂盒及其使用方法
KR102903735B1 (ko) 담관암종의 표지자로서의 timp1
KR101652894B1 (ko) 대장암에 대한 신규 바이오마커 및 그의 용도
CN117129681A (zh) 乳腺癌相关的生物标志物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20181107

Address after: Vitoria, Australia

Applicant after: Visual technology biology Pte Ltd

Address before: Campbell, Australian Capital

Applicant before: Commonwealth Scientific and Industrial Research Organisation

GR01 Patent grant
GR01 Patent grant